Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Brief Summary: This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.


Options:
A: Arm Label: AIN457 300mg s.c every 2 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 300mg s.c. every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 150mg s.c every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Placebo s.c every 2 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c every 2 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c every 4 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c. every 4 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c every 2 weeks
B: Arm Label: AIN457 300mg s.c weekly for 3 weeks; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 300mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 150mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: Placebo s.c weekly for 3 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c weekly for 3 weeks | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c at baseline and Week 2 | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c at baseline and Week 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c weekly for 3 weeks
C: Arm Label: AIN457C 300 mg every 2 week dosage regimen; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457C 300 mg monthly dosage regimen; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457C 300 mg every 2 week dosage regimen | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457C 300 mg monthly dosage regimen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: Prednisone | Arm Label: Mycophenolate Mofetil; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil, Drug: Prednisone | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Methotrexate, Mycophenolate Mofetil

Answer: A